|
|
|
 |
|
|
 |
News and Press Releases |
 |
Almac’s Ground-breaking AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma
24/06/14 CRAIGAVON, UK: The Almac Group Ltd, Is pleased to announce plans to make its ALM AADx assay - a gene expression test developed by its Diagnostics Business Unit - available for clinical use in 2015. Further validation
of the test in ovarian cancer is on track for completion by the end of
this year following the first validated results for a patient cohort,
unveiled last month at ASCO’s annual meeting. Following this meeting,
Almac has experienced a significant volume of enquiries from Pharma
companies seeking to develop companion diagnostics strategies.
More info >> |
|
 |
White Papers |
 |
|
Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences
Myoderm
Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >> |
|
 |
Industry Events |
 |
3rd Biomarkers in Diagnostics & Therapeutics 2014 (BDT2014)
24-25 September 2014, Singapore
The global biomarkers
market displays high growth potential in the near future with a projected value
of 40.8 billion by 2018.
More info >> |
|
|
